Abstract-The optimal blood pressure (BP) goal in patients with diabetes mellitus remains controversial. We examined whether benefits and risks of intensified antihypertensive therapy in diabetes mellitus are influenced by either baseline BP or cardiovascular disease (CVD) risk. We studied 10 948 people with diabetes mellitus, at moderate-to-high risk, in the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation). Cox models were used to determine whether baseline BP category or CVD risk modified the outcomes of combination perindopril-indapamide treatment, compared with placebo. During 4.3 years of follow-up, treatment with perindopril-indapamide versus placebo reduced mortality and major vascular (macrovascular or microvascular) events.
T he blood pressure (BP) threshold for initiation of antihypertensive treatment among patients with diabetes mellitus remains controversial. [1] [2] [3] This uncertainty complicates the care of these patients because the risk of future cardiovascular events associated with the presence of diabetes mellitus is considered equivalent to that of people who have previously had a myocardial infarction. 4 In addition, the prevalence of hypertension in patients with diabetes mellitus is high. 5, 6 In adults without diabetes mellitus, there is persuasive recent trial evidence to support BP targets that are lower than were previously advised. In SPRINT (Systolic Blood Pressure Intervention Trial), which included individuals with a high risk of cardiovascular disease (CVD), those randomized to a systolic BP (SBP) target of <120 mm Hg had a lower rate of death and cardiovascular events compared with their counterparts randomized to an SBP target of <140 mm Hg. 7 Also, in the HOPE-3 study (Heart Outcomes Prevention Evaluation-3), there was a reduction in cardiovascular events among patients with intermediate risk randomized to more intensive BP reduction who were in the upper third of the distribution of baseline SBP (>143 mm Hg). 8 However, none of those in SPRINT and only 6% of HOPE-3 participants had diabetes mellitus. Trial results in diabetes mellitus are inconsistent. The UKPDS (United Kingdom Prospective Diabetes Study) supports the use of intensive BP reduction in adults with diabetes mellitus, since the incidence of cardiovascular complications was 12% lower for each 10-mm Hg decrease in SBP, down to SBP levels <120 mm Hg. 9 It should be noted that this trial, initiated >25 years ago, was associated with initial and achieved BPs well above what would be considered clinically safe today (making it less applicable to contemporary practice considerations). By contrast, in the more contemporary ACCORD trial (Action to Control Cardiovascular Risk in Diabetes), participants randomized to intensive therapy to an SBP target of <120 mm Hg did not show a significant reduction in the primary combined cardiovascular outcome compared with those randomized to an SBP target of <140 mm Hg. 10 It is unclear why individuals with diabetes mellitus would not benefit from an SBP goal <140 mm Hg as much as do nondiabetics. Possible explanations for a lack of benefit of intensive therapy may be medication side effects, such as renal impairment, adverse effects due to more hypotensive effects, such as falls, or electrolyte disturbances and reduction in diastolic BP (DBP), resulting in worsening coronary perfusion. 11 Guidelines do not have a consistent SBP and DBP goal for adults with diabetes mellitus and hypertension, although there is consensus that risk should be individualized. The American Diabetes Association recommends an SBP/ DBP goal of 140/90 mm Hg with an SBP/DBP goal of 130/80 mm Hg for high-risk individuals if it can be achieved without undue burden. 3 In contrast, the 2017 American College of Cardiology/American Heart Association BP guideline recommends an SBP/DBP goal of 130/80 mm Hg for all adults with diabetes mellitus. 1 Similarly, the European Society of Cardiology recently updated their guidelines to recommend an SBP target <130 mm Hg for patients <65 years of age and <140 mm Hg for patients >65 years of age and a DBP target of <80 mm Hg. 2 Some additional support for intensive BP treatment among diabetics came from the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation). In this randomized controlled trial, participants were randomized to intensive therapy with fixed combination of perindopril-indapamide or placebo with an average reduction of BP of 5.6/2.2 mm Hg in the active treatment arm. There was a 9% reduction in major macrovascular or microvascular events and an 18% reduction in cardiovascular mortality with more intensive therapy. 12 Given these results and recent guidelines, we set out to examine whether the effects of intensification of BP therapy among people with diabetes mellitus in the ADVANCE trial 12 differed by baseline SBP, DBP, or estimated cardiovascular risk.
Methods
Details of the ADVANCE trial appear elsewhere. [12] [13] [14] Briefly, the study was a multicenter, randomized controlled trial of 11 140 patients who had type 2 diabetes mellitus with a history of CVD or at least one other CVD risk factor. The study had a 2-by-2 factorial design with participants randomized to intensive or standard glucose control and to fixed-dose perindopril 4 mg with indapamide 1.25 mg or placebo.
In this study, we focus on BP management and, therefore, randomization to perindopril-indapamide versus placebo. All participants provided written informed consent. The ADVANCE trial data, analytic methods, and study materials are not available to other researchers.
Participants' details were obtained at baseline, including demographics, medical history, and medications. Weight was measured in kilograms and height in meters. Body mass index was calculated as weight in kilograms divided by height in meters squared. After the individual rested for 5 minutes, SBP and DBP were taken as the mean of 2 attended measurements made while seated using an automated sphygmomanometer (Omron HEM-705CP; Tokyo, Japan). Current smoking, current alcohol drinking, fasting lipids, hemoglobin A1c, and serum creatinine (and estimated glomerular filtration rate using the modified diet in renal disease equation) were also recorded.
Outcomes
The primary outcome in ADVANCE was the composite of major macrovascular and microvascular events (hereafter referred to as a major vascular event). Major macrovascular events were cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Major microvascular events were new or worsening nephropathy (defined as macroalbuminuria, doubling of serum creatinine to ≥200 µmol/L, need for renal replacement therapy, or death because of renal disease) or retinopathy (defined as proliferative retinopathy, macular edema, diabetes mellitus-related blindness, or retinal photocoagulation therapy). In the current study, we considered this and all-cause mortality as twin primary efficacy outcomes. Secondary outcomes were the individual components of the major vascular disease end points. These outcomes were adjudicated by an independent End Point Adjudication Committee and coded using the International Classification of Diseases, Tenth Revision. We also analyzed serious adverse events, leading to discontinuation of study treatment (active or placebo), as recorded at local clinics in study visits during the trial. Cough and hypotension or dizziness were key adverse events recorded in ADVANCE.
Statistical Analyses
Participants were divided into 6 categories using baseline SBP: <120, 120 to 129, 130 to 139, 140 to 149, 150 to 159, and ≥160 mm Hg. Results were also generated according to a binary split at 140 mm Hg baseline SBP. Baseline DBP was similarly split into 4 groups, with thresholds at 70, 80, and 90 mm Hg and also using a binary split at 90 mm Hg. In secondary analyses of components of major vascular events, in which numbers in subgroups were relatively small, only the binary strata were analyzed.
The 10-year risk of atherosclerotic CVD (ASCVD) was estimated using the pooled cohort risk equations, as described by the American College of Cardiology/American Heart Association guidelines, 15, 16 and was analyzed in 2 groups, <20% and ≥20%, chosen to allow a sufficient number of events in the lower risk category, bearing in mind the relatively high-risk nature of the ADVANCE population. Roughly, one-third of ADVANCE participants had a history of CVD at baseline; these were included in the ≥20% group. People for whom it was not possible to compute the ASCVD risk were excluded from all analyses. Mean BP levels during the follow-up period were calculated by linear mixed models, according to randomized treatment and baseline 10-year ASCVD risk or baseline SBP category.
We modeled the association between randomized treatment (perindopril plus indapamide versus placebo) and major vascular events and death, stratified by baseline SBP, DBP, ASCVD categories, and combinations of SBP and DBP categories and of SBP and ASCVD categories, using Cox proportional hazards models. Tests for interaction between the stratification variable and treatment were performed by adding interaction terms to the relevant model. Adverse events leading to discontinuation were analyzed using risk ratios, and interaction tests came from logistic regression models. A priori, no adjustment was made for covariates (as in the prespecified analysis plan for ADVANCE) or for multiple statistical testing. Analyses were performed using SAS Enterprise Guide, version 7.11, and Stata, version 13.1. We considered a 2-sided P <0.05 as statistically significant.
Results
After excluding 14 patients because of missing lipid results, and 178 patients aged ≥80 years, 10 948 participants were included in the final analyses. Participants with SBP ≥140 mm Hg were more likely to be women, have higher body mass index and urinary albumin:creatinine ratio, and taking (10) 153 (12) 127 (10) 160 (17) DBP, mm Hg 74 (8) 85 (10) 75 (9) 85 (10) Heart rate, bpm 76 (11) 77 (12) 73 (12) Variables presented as mean (SD) or percentage. The ASCVD Pooled Cohort Risk Equation was used to estimate 10-y risk of ASCVD. ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; SBP, systolic blood pressure; and UACR, urine albumin-to-creatinine ratio.
*Median (interquartile interval). †Randomized treatment with perindopril-indapamide was not included.
BP-lowering medication before randomization, whereas they were less likely to live in Asia and be currently smoking, compared with those with SBP <140 mm Hg, irrespective of whether ASCVD risk was <20% or ≥20%. Participants with ASCVD risk ≥20% were more likely to be men, be current smokers, or be on BP-lowering treatment compared with participants with ASCVD risk <20% (Table) . The baseline characteristics of participants stratified by DBP groups are shown in Table S1 in the online-only Data Supplement, and baseline characteristics by randomized treatment, after first stratifying by baseline SBP and 10-year ASCVD risk, are shown in Table S2 . Compared with the placebo arm, the mean on-treatment BP was lower in the intervention arm regardless of baseline 10-year ASCVD risk or baseline SBP category (Figure 1 ). In the SBP <140 mm Hg group, the on-treatment BP was <130/80. Although no reduction in BP is noted in the run-in period in the SBP <140 mm Hg group, there is a difference in SBP between the placebo and intervention groups on follow-up after randomization in all groups.
During a mean follow-up of 4.3 years, there were 837 deaths and 966 major vascular events. The fixed-dose combination of perindopril-indapamide reduced major vascular events (hazard ratio, 0.91; 95% CI, 0.83-0.997) and all-cause mortality (hazard ratio, 0.86; 95% CI, 0.75-0.99; Figure 2 ). There was no evidence of heterogeneity in the treatment effects across SBP subgroups for all-cause mortality (P=0.36) or major vascular events (P=0.83). Similar findings were present within subgroups defined by baseline DBP levels or combination of SBP and DBP (Figures 3 and 4A ; P for heterogeneity, ≥0.20). Overall findings were broadly the same for the individual components of major vascular events (Figures S1 through S3; P for heterogeneity, ≥0.19).
There was no evidence of heterogeneity in the effect of randomized treatment across subgroups defined by ASCVD risk ( Figure 4B ; Figure S4 ), although the P for heterogeneity for major vascular events was borderline at P of 0.08. When results for the broad subgroups of baseline SBP (split at 140 mm Hg) or DBP (split at 90 mm Hg) levels were compared within levels of ASCVD risk (<20% or ≥20%), there was, again, no evidence of heterogeneity for the primary outcomes (P ≥0.17) or for the secondary outcomes (P ≥0.08; Figures S5 and S6) .
Although adverse events leading to permanent discontinuation were more frequently present in the perindoprilindapamide group, compared with placebo, there was no statistically significant heterogeneity in the effects across subgroups defined by baseline SBP, DBP, or 10-year ASCVD risk ( Figure 5 ; Figures S7 and S8; all P for heterogeneity, ≥0.08).
Discussion
This study builds on previous reports of BP-lowering treatment in patients with diabetes mellitus. First, we found that more intense antihypertensive treatment, using a fixed regimen consisting of perindopril-indapamide, reduced allcause mortality and major vascular events in patients with diabetes mellitus, irrespective of baseline BP or 10-year ASCVD risk. Regardless of the baseline SBP or ASCVD group, the intervention arm had lower on-treatment SBP compared with the placebo arm. For those with baseline SBP <140 mm Hg, most of the benefit for more intensive therapy was driven by the group with baseline SBP of 130 to 139 mm Hg-a finding that supports current American College of Cardiology/American Heart Association guidelines. 1 There was also no evidence of heterogeneity in the effects of randomized treatment, comparing whether SBP was below 140 mm Hg or not or DBP was below 90 mm Hg or not, among both those with <20% 10-year ASCVD risk and among those with higher ASCVD risk. Second, we found no statistical evidence that cough and in particular hypotension/dizziness, both side effects common to antihypertensive therapy, were more likely to lead to permanent drug discontinuation in those with baseline SBP <140 mm Hg versus baseline SBP ≥140 mm Hg, compared with placebo.
Previous studies have demonstrated the relative benefit of SBP <140 mm Hg in the general population. In a meta-analysis of 1 million individuals in prospective observational studies, the risk of ASCVD death increased above SBP >115 mm Hg in untreated adults. 17 Another meta-analysis of randomized control trials reported that compared with participants who had a baseline SBP <130, those with baseline SBP ≥130 mm Hg were at increased stroke and all-cause mortality risk. 18 These findings were corroborated by the SPRINT trial findings among adults without diabetes mellitus but with a mean 10-year ASCVD risk of 24.8%. Participants were randomized to intensive therapy with a target SBP <120 mm Hg or standard therapy with target <140 mm Hg. The intensive therapy arm had a lower rate of the primary composite outcome of myocardial infarction, other acute coronary syndromes, stroke, heart failure, or CVD death. 7 Although individuals with diabetes mellitus were not included in SPRINT, post hoc analyses of participants with prediabetes or normoglycemia also demonstrated a significant reduction in the primary outcome with intensive therapy in both groups. Nonetheless, arguments against an intensive BP goal in patients with diabetes mellitus are somewhat supported by the ACCORD trial. In this trial, there was no reduction in the primary combined outcome of nonfatal myocardial infarction, stroke, or cardiovascular death with intensive SBP therapy to target <120 mm Hg compared with standard therapy target of <140 mm Hg among diabetics. 10 However, ACCORD does not rule out benefit to a target <130 mm Hg and, indeed, showed a trend toward benefit of intensive BP control to <120 mm Hg with a significant reduction in stroke and a point estimate for the primary composite outcome that was in favor of intensive therapy. In addition, the actual number of events was significantly lower than expected reducing the power of the ACCORD analysis.
Further support for a potential benefit for lower BP targets, irrespective of diabetes mellitus status, comes from an analysis combining results from both ACCORD and SPRINT, which showed that intensive BP management was associated with a reduction in stroke, heart failure, and each study's primary outcome, without evidence of heterogeneity in effect across both studies. 20 In addition, a recent post hoc analysis from ACCORD suggests that the benefit of intensive BP control may potentially be related to an interaction with the intensity of glycemic control in the factorial design of the study, with patients randomized to standard glycemic treatment (HbA1c goal of 7%-7.9%) demonstrating statistically significant benefit from more aggressive BP treatment, whereas those receiving more intensive glycemic control did not. 21, 22 In terms of baseline CVD risk, the benefits of intensive BP treatment seen in ADVANCE are consistent with the SPRINT study results, which also included moderate-to-high risk adults. This finding contrasts with the lower risk patient population in the HOPE-3 study where no reduction in CVD events was found with more intense antihypertensive treatment in the overall sample. 7, 8 In addition, our results are also supported by a meta-analysis demonstrating that lowering of SBP with intensive BP treatment regimens is associated with a greater absolute risk reduction, but similar relative risk reductions, in the 5-year burden of cardiovascular events in groups stratified as having a high predicted ASCVD risk, compared with lower ASCVD risk groups. 23 Further, this finding matches well with a recent subgroup analysis of diabetic patients in ACCORD who had elevated 10-year ASCVD risk (mean, ≈15%) and were shown to have a reduction in the composite primary outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, revascularization, and heart failure with more intensive BP lowering. 24 The current study also adds to the findings of a meta-analysis of randomized trials showing a reduction in ASCVD events of intensive BP-lowering treatment in patients with diabetes mellitus and a mean SBP of <140 mm Hg. 25, 26 Furthermore, a recent study indicates that >95% of US adults with diabetes mellitus and SBP/DBP ≥130/80 mm Hg have a 10-year ASCVD risk ≥10% or a history of CVD. 27 Taken together with the results from the current study, this suggests that most adults with type 2 diabetes mellitus taking antihypertensive medication would benefit from a BP goal of <130/80 mm Hg, thus raising the possibility that the current American Diabetes Association guidelines 3 may be too conservative. There was no evidence to suggest that the effects of BP-lowering treatment on the risk of adverse side effects leading to discontinuation would differ according to baseline BP or ASCVD risk. Importantly, such adverse events were negligible, compared with clinical events, in the intervention group, although the disadvantage in statistical terms is that the small number of adverse events recorded increases the uncertainty in these analyses. Furthermore, we did not evaluate all possible adverse events, such as electrolyte abnormalities and renal dysfunction.
The current analysis has several strengths. We included a large number of individuals with diabetes mellitus and high ASCVD risk, with a comprehensive ascertainment of demographics and clinical history and regular follow-up for adverse events. In addition, participants were drawn from 215 sites from 20 countries. However, this study is a post hoc analysis of a randomized controlled trial, which was not originally designed, or powered, to study the distinct baseline SBP groups included in this study. The most recent guidelines 1 recommend pharmacological therapy for a 10-year ASCVD risk of ≥10%. However, because of the small number of individuals with a 10-year ASCVD risk of <10% in our study, which would, therefore, result in inadequate power for analysis, we chose a cutoff of 20%. This limits our ability to comment whether there would be any difference with intensive BP therapy between individuals with <10% and ≥10% ASCVD risk. Although we found no evidence for statistical heterogeneity and while the CIs include evidence for benefit with more intensive BP therapy, our results also cannot rule out the possibility that people at lower ASCVD risk may not benefit from more intensive treatment. Further, the ADVANCE trial used a specific antihypertensive regimen, and the benefit seen may be drug specific and may not be more widely applicable to other antihypertensive medications. In addition, in our study population, the majority of individuals were already on antihypertensives at baseline, and, therefore, the active arm represents an intensification of BP treatment rather than initiation of treatment of BP.
In conclusion, in the current study, ADVANCE participants with diabetes mellitus benefitted from more intensive BP treatment regardless of baseline BP and of 10-year estimated ASCVD risk. This is consistent with recent guidelines recommending a lower BP target than the previous target of 140/90 mm Hg.
1,2 Nonetheless, a future randomized controlled trial that evaluates whether adults with diabetes mellitus benefit from intensive therapy to an SBP goal <130 mm Hg, compared with SBP <140 mm Hg, is warranted. It also remains unclear how intensive glycemic control interacts with intensive BP management, especially with the incorporation of newer medications such as Sodium Glucose Transport Protein 2 inhibitors.
Perspectives
There has been significant debate regarding the threshold for initiation of antihypertensive treatment among individuals with diabetes mellitus. The results of our study support intense BP treatment not only among individuals without diabetes mellitus as supported by the SPRINT study but also among individuals with diabetes mellitus. This is consistent with recent recommendations from the 2017 American College of Cardiology/American Heart Association BP guidelines, which recommend a BP target of <130/80 mm Hg.
